Table 1 TAMs as promising targets for CRC treatment
Drug | Type | Target | Function | PMID |
|---|---|---|---|---|
Reprogramming TAMs | ||||
 Anti-MARCO IgG | Monoclonal antibody | MARCO | Increasing population of M1 macrophages and decreasing population of M2 macrophages | 27210762 |
 Tasquinimod | S100A9 inhibitor | S100A9 | Leading to the transformation of M2 macrophages into M1 macrophages | 26673090 |
 Actibind (T2 RNases) | Ribonuclease | N/A | Rebalancing the ratio of M1/M2 macrophages and recruiting CD8 + T cells | 32197460 |
 EZH2 inhibitor | Small-molecule inhibitors | STAT3 | Leading to the transformation of M2 macrophages into M1 macrophages | 35432300 |
Inhibiting TAMs survival | ||||
 Pexidartinib (PLX3397) | CSF1R inhibitor | CSF1R | Depleting M2 macrophages and increasing CD8+ T cell infiltration | 36600555 |
 Trifluridine/Tripiracil (FTD/TPI) | Combination drug of trifluridine and tipiracil | N/A | Depleting TAMs | 31611243 |
 Oxaliplatin | Platinum based chemotherapy drugs | N/A | Depleting TAMs | 31611243 |
 M2pep | M2 macrophage-targeting peptide | Macrophages | Reducing M2 macrophages | 24046373 |
 RG7155 | Monoclonal antibody | CSF-1R | Depleting TAMs and increasing CD8+/CD4+ T cell ratio | 24898549 |
 Lenvatinib | Tyrosine kinase inhibitor | VEGF and FGF receptors | Reducing TAMs numbers | 30811474 |
Inhibiting TAMs recruitment | ||||
 NT157 | IGF-1R inhibitor | IGF-1R and STAT3 | Inhibiting expression of CCL2 to inhibit recruitment of TAMs | 26364612 34580284 |
 AMG 820 | CSF1R antibody | CSF1 | blocking the CSF1-CSF1R signaling to inhibit recruitment of TAMs | 28655795 35718267 |
 PF-04136309 | CCR2 inhibitor | CCR2 | Inhibiting CCL2 binding to CCR2 to inhibit recruitment of TAMs | 34729117 34580284 |